Refining targeted therapies in chronic myeloid leukemia: development and application of nilotinib, a step beyond imatinib

The BCR-ABL kinase inhibitor imatinib mesylate is currently the standard therapy for patients with chronic myeloid leukemia (CML). Despite the remarkable results achieved with imatinib for the treatment of CML, the emergence of resistance to this drug has become a significant problem. Mutations with...

Descripción completa

Detalles Bibliográficos
Autores principales: Breccia, Massimo, Alimena, Giuliana
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2008
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2994207/
https://www.ncbi.nlm.nih.gov/pubmed/21127752

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2994207/
https://www.ncbi.nlm.nih.gov/pubmed/21127752

Ejemplares similares